{"id":"https://openalex.org/W2144149552","doi":"https://doi.org/10.3109/01480545.2010.494667","title":"Establishment of simultaneous treatment model with citrate for preventing nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats","display_name":"Establishment of simultaneous treatment model with citrate for preventing nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats","publication_year":2010,"publication_date":"2010-11-25","ids":{"openalex":"https://openalex.org/W2144149552","doi":"https://doi.org/10.3109/01480545.2010.494667","mag":"2144149552","pmid":"https://pubmed.ncbi.nlm.nih.gov/21105859"},"language":"en","primary_location":{"id":"doi:10.3109/01480545.2010.494667","doi":"https://doi.org/10.3109/01480545.2010.494667","is_oa":false,"landing_page_url":"https://doi.org/10.3109/01480545.2010.494667","pdf_url":null,"source":{"id":"https://openalex.org/S17820993","display_name":"Drug and Chemical Toxicology","issn_l":"0148-0545","issn":["0148-0545","1525-6014"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug and Chemical Toxicology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052010897","display_name":"Naoki Ashizawa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405266857","display_name":"Fuji Yakuhin Co., Ltd. (Japan)","ror":"https://ror.org/0031t6k06","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405266857"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Naoki Ashizawa","raw_affiliation_strings":["Research Laboratories, Fuji Yakuhin Co., Ltd., Saitama, Japan. L2-26899@fujiyakuhin.co.jp","Research Laboratories 2, Fuji Yakuhin Co., Ltd., Saitama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Laboratories, Fuji Yakuhin Co., Ltd., Saitama, Japan. L2-26899@fujiyakuhin.co.jp","institution_ids":["https://openalex.org/I4405266857"]},{"raw_affiliation_string":"Research Laboratories 2, Fuji Yakuhin Co., Ltd., Saitama, Japan","institution_ids":["https://openalex.org/I4405266857"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Takeo Shimo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405266857","display_name":"Fuji Yakuhin Co., Ltd. (Japan)","ror":"https://ror.org/0031t6k06","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405266857"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takeo Shimo","raw_affiliation_strings":["Research Laboratories 2, Fuji Yakuhin Co., Ltd., Saitama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Laboratories 2, Fuji Yakuhin Co., Ltd., Saitama, Japan","institution_ids":["https://openalex.org/I4405266857"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089906631","display_name":"Koji Matsumoto","orcid":"https://orcid.org/0000-0003-4319-1970","observed_orcids":["https://orcid.org/0000-0003-4319-1970"]},"institutions":[{"id":"https://openalex.org/I4405266857","display_name":"Fuji Yakuhin Co., Ltd. (Japan)","ror":"https://ror.org/0031t6k06","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405266857"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Koji Matsumoto","raw_affiliation_strings":["Research Laboratories 2, Fuji Yakuhin Co., Ltd., Saitama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Laboratories 2, Fuji Yakuhin Co., Ltd., Saitama, Japan","institution_ids":["https://openalex.org/I4405266857"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090363784","display_name":"Tetsuya Taniguchi","orcid":"https://orcid.org/0000-0002-2244-2999","observed_orcids":["https://orcid.org/0000-0002-2244-2999"]},"institutions":[{"id":"https://openalex.org/I4405266857","display_name":"Fuji Yakuhin Co., Ltd. (Japan)","ror":"https://ror.org/0031t6k06","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405266857"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tetsuya Taniguchi","raw_affiliation_strings":["Research Laboratories 2, Fuji Yakuhin Co., Ltd., Saitama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Laboratories 2, Fuji Yakuhin Co., Ltd., Saitama, Japan","institution_ids":["https://openalex.org/I4405266857"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089770991","display_name":"Mitsuyoshi Moto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405266857","display_name":"Fuji Yakuhin Co., Ltd. (Japan)","ror":"https://ror.org/0031t6k06","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405266857"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Mitsuyoshi Moto","raw_affiliation_strings":["Research Laboratories 2, Fuji Yakuhin Co., Ltd., Saitama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Laboratories 2, Fuji Yakuhin Co., Ltd., Saitama, Japan","institution_ids":["https://openalex.org/I4405266857"]}]},{"author_position":"last","author":{"id":null,"display_name":"Osamu Nagata","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405266857","display_name":"Fuji Yakuhin Co., Ltd. (Japan)","ror":"https://ror.org/0031t6k06","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405266857"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Osamu Nagata","raw_affiliation_strings":["Research Laboratories 2, Fuji Yakuhin Co., Ltd., Saitama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Laboratories 2, Fuji Yakuhin Co., Ltd., Saitama, Japan","institution_ids":["https://openalex.org/I4405266857"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5052010897"],"corresponding_institution_ids":["https://openalex.org/I4405266857"],"apc_list":null,"apc_paid":null,"fwci":0.2452,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.61992128,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"34","issue":"2","first_page":"151","last_page":"161"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11139","display_name":"Gout, Hyperuricemia, Uric Acid","score":0.6660000085830688,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11139","display_name":"Gout, Hyperuricemia, Uric Acid","score":0.6660000085830688,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10606","display_name":"Kidney Stones and Urolithiasis Treatments","score":0.11869999766349792,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12429","display_name":"Chemotherapy-induced organ toxicity mitigation","score":0.044199999421834946,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/xanthine-oxidoreductase-inhibitors","display_name":"xanthine oxidoreductase inhibitors","score":0.9649999737739563},{"id":"https://openalex.org/keywords/citrate","display_name":"citrate","score":0.8289999961853027},{"id":"https://openalex.org/keywords/nephropathy-prevention","display_name":"nephropathy prevention","score":0.75},{"id":"https://openalex.org/keywords/urinary-bladder-carcinogenesis","display_name":"urinary bladder carcinogenesis","score":0.9290000200271606},{"id":"https://openalex.org/keywords/urinary-citrate","display_name":"urinary citrate","score":0.6449999809265137},{"id":"https://openalex.org/keywords/dosing-interval","display_name":"dosing interval","score":0.8740000128746033},{"id":"https://openalex.org/keywords/renal-lesions","display_name":"renal lesions","score":0.6159999966621399}],"concepts":[{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7478302121162415},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5911362767219543},{"id":"https://openalex.org/C2779470414","wikidata":"https://www.wikidata.org/wiki/Q50980","display_name":"Xanthine","level":3,"score":0.5816820859909058},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5050185322761536},{"id":"https://openalex.org/C10146269","wikidata":"https://www.wikidata.org/wiki/Q185557","display_name":"Excretion","level":2,"score":0.4953111708164215},{"id":"https://openalex.org/C2779032678","wikidata":"https://www.wikidata.org/wiki/Q159683","display_name":"Citric acid","level":2,"score":0.440591961145401},{"id":"https://openalex.org/C2780742167","wikidata":"https://www.wikidata.org/wiki/Q6460572","display_name":"Sodium citrate","level":2,"score":0.4208899140357971},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3473855257034302},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.2819773852825165},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.12003615498542786},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002614","descriptor_name":"Chelating Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D002614","descriptor_name":"Chelating Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D007674","descriptor_name":"Kidney Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D007674","descriptor_name":"Kidney Diseases","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D007674","descriptor_name":"Kidney Diseases","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009570","descriptor_name":"Nitriles","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D011916","descriptor_name":"Rats, Inbred F344","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014968","descriptor_name":"Xanthine Dehydrogenase","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D019343","descriptor_name":"Citric Acid","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D019343","descriptor_name":"Citric Acid","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D019820","descriptor_name":"Xanthine","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.3109/01480545.2010.494667","doi":"https://doi.org/10.3109/01480545.2010.494667","is_oa":false,"landing_page_url":"https://doi.org/10.3109/01480545.2010.494667","pdf_url":null,"source":{"id":"https://openalex.org/S17820993","display_name":"Drug and Chemical Toxicology","issn_l":"0148-0545","issn":["0148-0545","1525-6014"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug and Chemical Toxicology","raw_type":"journal-article"},{"id":"pmid:21105859","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21105859","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug and chemical toxicology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":19,"referenced_works":["https://openalex.org/W20949652","https://openalex.org/W1795093297","https://openalex.org/W1864560367","https://openalex.org/W1970540527","https://openalex.org/W2032310321","https://openalex.org/W2037140399","https://openalex.org/W2047276432","https://openalex.org/W2067427297","https://openalex.org/W2068355671","https://openalex.org/W2081034228","https://openalex.org/W2116570526","https://openalex.org/W2126739473","https://openalex.org/W2161580767","https://openalex.org/W2170834657","https://openalex.org/W2327678275","https://openalex.org/W2409794069","https://openalex.org/W2412167598","https://openalex.org/W2419022866","https://openalex.org/W2474113318"],"related_works":["https://openalex.org/W2161580767","https://openalex.org/W2067427297","https://openalex.org/W1966020698","https://openalex.org/W2131510463","https://openalex.org/W2116570526","https://openalex.org/W2340698024","https://openalex.org/W2088366209","https://openalex.org/W2952128802","https://openalex.org/W2951337539","https://openalex.org/W2066342421"],"abstract_inverted_index":{"As":[0,124],"a":[1,20,64,75,87,125,180],"precedent":[2],"study":[3,91,182,214,237],"for":[4,31,159,234],"elucidating":[5],"the":[6,27,32,78,110,116,127,160,164,200,212,217,228,235],"mechanism":[7],"of":[8,55,77,80,112,119,130,157,189,219,238,244],"possible":[9],"urinary":[10,50,56,240],"bladder":[11,241],"carcinogenesis":[12,242],"due":[13],"to":[14,134,169],"xanthine":[15,21,57,153],"crystals":[16],"induced":[17],"by":[18,92,106,183],"FYX-051,":[19],"oxidoreductase":[22],"inhibitor,":[23],"we":[24,84],"have":[25],"determined":[26],"experimental":[28],"conditions":[29,111],"suitable":[30],"52-week":[33],"simultaneous":[34,89,184],"treatment":[35,42,90,149,162,185,247],"with":[36,43],"citrate":[37,44,51,81,102,131,158,192,196,221],"in":[38],"F344":[39],"rats.":[40],"Simultaneous":[41],"and":[45,53,101,121,163,175,191,225],"FYX-051":[46,98,190],"produced":[47],"both":[48],"increased":[49],"excretion":[52],"suppression":[54],"deposition":[58],"at":[59,137,142,172,186],"around":[60],"4":[61,138],"hours":[62,72],"after":[63],"single":[65],"dosing,":[66],"but":[67,140],"these":[68],"effects":[69],"disappeared":[70],"2":[71],"later,":[73],"indicating":[74],"lack":[76],"durability":[79],"effects.":[82],"Next,":[83],"carried":[85],"out":[86],"7-day":[88],"two":[93,220],"daily":[94],"treatments,":[95],"that":[96,204,216,227],"is,":[97],"(6":[99],"mg/kg)":[100,194],"(2,000":[103,193],"mg/kg),":[104,198],"followed":[105],"citrate-alone":[107],"treatment,":[108],"under":[109,199],"selected":[113],"dosing":[114,122,128,165],"intervals,":[115],"second":[117,161],"dose":[118,156],"citrate,":[120],"volume.":[123],"result,":[126],"interval":[129,218],"was":[132],"found":[133,168],"be":[135,170,208,232],"optimal":[136],"hours,":[139,146],"not":[141],"3":[143,187],"or":[144],"5":[145],"because":[147,243],"this":[148],"completely":[150],"inhibited":[151],"intrarenal":[152],"deposition.":[154],"The":[155],"volume":[166],"were":[167],"sufficient":[171],"1,500":[173],"mg/kg":[174,188],"10":[176],"mL/kg,":[177],"respectively.":[178],"Subsequently,":[179],"4-week":[181],"+":[195],"(1,500":[197],"improved":[201,229],"conditions,":[202],"revealed":[203],"renal":[205],"lesions":[206],"could":[207],"drastically":[209],"inhibited.":[210],"Thus,":[211],"present":[213],"demonstrated":[215],"treatments":[222],"is":[223],"pivotal":[224],"indicated":[226],"model":[230],"would":[231],"useful":[233],"mechanistic":[236],"FYX-051-induced":[239],"an":[245],"easier":[246],"method":[248],"than":[249],"our":[250],"previous":[251],"model.":[252]},"counts_by_year":[{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}